Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: RANEXA

« Back to Dashboard
Ranexa is a drug marketed by Gilead and is included in one NDA. It is available from three suppliers. There are ten patents protecting this drug.

This drug has ninety-two patent family members in twenty-nine countries.

The generic ingredient in RANEXA is ranolazine. There are ten drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ranolazine profile page.

Summary for Tradename: RANEXA

Patents:10
Applicants:1
NDAs:1
Suppliers: see list3

Clinical Trials for: RANEXA

Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients
Status: Completed Condition: End-stage Renal Disease; Cardiovascular Disease

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)
Status: Completed Condition: Atrial Fibrillation

Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion
Status: Completed Condition: Persistent Atrial Fibrillation

Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)
Status: Recruiting Condition: Diabetic Peripheral Neuropathic Pain

Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine
Status: Completed Condition: Type 2 Diabetes Mellitus

Ranolazine in Ischemic Cardiomyopathy
Status: Completed Condition: Cardiomyopathy; Chest Pain; Dyspnea

Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy
Status: Completed Condition: Diabetes Mellitus, Type 2

Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging
Status: Completed Condition: Myocardial Perfusion Imaging; Myocardial Ischemia

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg
Status: Completed Condition: Type 2 Diabetes Mellitus

Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D
Status: Recruiting Condition: Diarrhea Predominant Irritable Bowel Syndrome

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-001Feb 12, 2007RXYes6,303,607<disabled><disabled>
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-002Jan 27, 2006RXNo6,617,328<disabled>Y<disabled>
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-001Feb 12, 2007RXYes6,864,258<disabled><disabled>
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-001Feb 12, 2007RXYes6,562,826<disabled><disabled>
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-002Jan 27, 2006RXNo6,479,496<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: RANEXA

Country Document Number Publication Date
Hungary0204409Apr 28, 2005
Czech Republic20022996Sep 17, 2003
Hungary0103844Apr 29, 2002
Poland348249May 20, 2002
Spain2234302Jun 16, 2005
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc